Adverse Cardiovascular Effects of Phenylephrine Eye Drops Combined with Intravenous Atropine

2020 ◽  
Author(s):  
Qingyu Li ◽  
Yang Gao ◽  
Yang Deng ◽  
Yong Wang ◽  
Jianxin Pang ◽  
...  
Keyword(s):  
Cardiovascular Effects ◽  
Eye Drops ◽  
Intravenous Atropine

scholarly journals Adverse Cardiovascular Effects of Phenylephrine Eye Drops Combined With Intravenous Atropine

2021 ◽  
Vol 11 ◽  
Author(s):  
Qingyu Li ◽  
Jianxin Pang ◽  
Yang Deng ◽  
Shaochong Zhang ◽  
Yong Wang ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Systolic Blood Pressure ◽  
General Anesthesia ◽  
Diastolic Blood Pressure ◽  
Cardiovascular Effects ◽  
Eye Drops ◽  
Intraocular Surgery ◽  
Atropine Treatment ◽  
Intravenous Atropine

Background: Phenylephrine and atropine can cause serious adverse effects when applied in combination. We investigated the effect of phenylephrine eye drops combined with intravenous atropine on the cardiovascular system in patients under general anesthesia undergoing intraocular surgery.Methods: The effects of the drugs were observed through clinical study. Thirteen patients undergoing intraocular surgery under general anesthesia were observed in this study; all were injected intravenously with atropine due to the oculocardiac reflex during surgery. To study the combination of drugs, an in vivo study was performed on rats. Seventy-two standard deviation rats that received phenylephrine eye drops and intravenous atropine treatment under general anesthesia were assessed, of which 18 treated with these drugs simultaneously were administered normal saline, neostigmine or esmolol. Blood pressure and heart rate were recorded and analyzed.Findings: The age of the patients ranged from seven to 14 years old with an average age of 10.7 years old, and 11 patients were male. In patients, 5% phenylephrine eye drops combined with intravenous atropine led to a significant heart rate increase and the increase lasted 20 min. The significant increase in diastolic blood pressure and systolic blood pressure lasted for 15 and 25 min, respectively. From five to 25 min after intravenous atropine treatment, the systolic blood pressure and diastolic blood pressure were both more than 20% higher than that at baseline. In rats, the changes in blood pressure and heart rate were independent of the phenylephrine and atropine administration sequence but were related to the administration time interval. The neostigmine group showed a significant decrease in blood pressure after the increase from the administration of phenylephrine and atropine.Interpretation: Phenylephrine eye drops combined with intravenous atropine have obvious cardiovascular effects that can be reversed by neostigmine. This drug combination should be used carefully for ophthalmic surgery, especially in patients with cardio-cerebrovascular diseases.

scholarly journals Association between Ophthalmic Timolol and Hospitalisation for Bradycardia

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Nicole L. Pratt ◽  
Emmae N. Ramsay ◽  
Lisa M. Kalisch Ellett ◽  
Tuan A. Nguyen ◽  
Elizabeth E. Roughead
Keyword(s):  
Beta Blocker ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Eye Drops ◽  
Continuous Exposure ◽  
Case Series Study ◽  
Increased Risk ◽  
Risk Period ◽  
Series Study ◽  
Remaining Time

Introduction. Ophthalmic timolol, a topical nonselective beta-blocker, has the potential to be absorbed systemically which may cause adverse cardiovascular effects. This study was conducted to determine whether initiation of ophthalmic timolol was associated with an increased risk of hospitalisation for bradycardia.Materials and Methods. A self-controlled case-series study was undertaken in patients who were hospitalised for bradycardia and were exposed to timolol. Person-time after timolol initiation was partitioned into risk periods: 1–30 days, 31–180 days, and >180 days. A 30-day risk period prior to initiating timolol was also included. All remaining time was considered unexposed.Results. There were 6,373 patients with at least one hospitalisation for bradycardia during the study period; 267 were exposed to timolol. Risk of bradycardia was significantly increased in the 31–180 days after timolol initiation (incidence rate ratio (IRR) = 1.93; 95% confidence interval (CI) 1.00–1.87). No increased risk was observed in the first 30 days or beyond 180 days of continuous exposure (IRR = 1.40; 95% CI 0.87–2.26 and IRR = 1.21; 95% CI 0.64–2.31, resp.).Conclusion. Bradycardia is a potential adverse event following timolol initiation. Practitioners should consider patient history before choosing a glaucoma regime and closely monitor patients after treatment initiation with topical nonselective beta-blocker eye drops.

CARDIOVASCULAR EFFECTS OF TIMOLOL EYE DROPS

InPharma ◽  
1980 ◽  
Vol 253 (1) ◽  
pp. 14-14
Keyword(s):  
Cardiovascular Effects ◽  
Eye Drops

Botulinium toxin therapy: Cardiovascular effects

1997 ◽  
Vol 103 (1) ◽  
pp. 172
Author(s):  
A Attanasio
Keyword(s):  
Cardiovascular Effects

Cannabis-associated arteritis

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen
Keyword(s):  
Systematic Review ◽  
Case Reports ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Causative Factor ◽  
Cannabis Use ◽  
Thromboangiitis Obliterans ◽  
Pathological Features ◽  
Scientific Support ◽  
Clinical And Pathological Features

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.

Some cardiovascular effects of the aqueous extract of the leaves of Starchytarpheta jamaicensis L. (Vahl)

Planta Medica ◽  
2006 ◽  
Vol 72 (11) ◽  
Author(s):  
M Idu ◽  
EKI Omogbai ◽  
F Amaechina ◽  
JE Ataman
Keyword(s):  
Aqueous Extract ◽  
Cardiovascular Effects

Adjuvant therapy of aspirin and cromoglycate 2% eye drops in vernal conjunctivitis

1989 ◽  
Vol 3 (1) ◽  
pp. 42 ◽  
Author(s):  
C. Srinivas
Keyword(s):  
Adjuvant Therapy ◽  
Eye Drops ◽  
Vernal Conjunctivitis

Cardiovascular effects of treatment with Liraglutide in a population with type 2 diabetes

2013 ◽  
Author(s):  
Marco Zavattaro ◽  
Flavia Prodam ◽  
Mauri Maria Grazia ◽  
Loredana Pagano ◽  
Marina Caputo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Effects

The Cardiovascular Effects of Energy Drinks

2020 ◽  
Vol 4 (2) ◽  
pp. 01-05
Author(s):  
Sara Cetin Sanlialp
Keyword(s):  
Cardiovascular Effects ◽  
Energy Drinks
Sign in / Sign up

Export Citation Format

Share Document